AAV-hTERT vs Tertomotide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Telomerase (hTERT) · full Alzheimer's Disease pipeline
AAV-hTERT
Developed by Libella Gene Therapeutics
NCT04133454 · Phase 1 · status unknown
All participants received the same single-dose treatment with no comparison group, randomization, or blinding, so the study cannot demonstrate a treatment effect. Results have not yet been posted.
No aligned efficacy figure on record for this race.
Tertomotide
Marketed by GemVax & KAEL
NCT05189210 · Phase 2 · completed
This was a randomized, quadruple-blind, placebo-controlled Phase 2 trial with 199 participants and a validated cognitive primary endpoint (ADAS-Cog11 change at week 52). The sponsor reports that neither GV1001 dose separated from placebo on the primary endpoint (4.14 and 4.31 points versus 4.30 for placebo). Registry results are not posted; the result comes from a company disclosure.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT05303701 (registry estimate)
Reported efficacy
Change from baseline in ADAS-Cog11 score at Week 52 (Baseline, Week 12, Week 26, Week 38, and Week 52): 52주 차 ADAS-cog11의 최소제곱평균값 변화량은 GV1001 0.56mg과 1.12mg 투약군에서 각각 4.14점, 4.31점으로 위약군 4.30점 (LS-mean change in ADAS-cog11 at week 52: GV1001 0.56 mg 4.14 points, 1.12 mg 4.31 points, placebo 4.30 points; not statistically significant) (missed)
Result source: NCT05189210
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AAV-hTERT | Tertomotide |
|---|---|---|
| CDR-SB, change | —Not reported | —Trial running · NCT05303701 |
| ADAS-Cog11, change | —Not reported | —Trial running · NCT05303701 |
| ADCS-ADL, change | —Not reported | —Trial running · NCT05303701 |
| MMSE, change | —Not reported | —Trial running · NCT05303701 |
| Amyloid PET, change (centiloids) | —Not reported | —Trial running · NCT05303701 |
CDR-SB, change
- AAV-hTERT
- —Not reported
- Tertomotide
- —Trial running · NCT05303701
ADAS-Cog11, change
- AAV-hTERT
- —Not reported
- Tertomotide
- —Trial running · NCT05303701
ADCS-ADL, change
- AAV-hTERT
- —Not reported
- Tertomotide
- —Trial running · NCT05303701
MMSE, change
- AAV-hTERT
- —Not reported
- Tertomotide
- —Trial running · NCT05303701
Amyloid PET, change (centiloids)
- AAV-hTERT
- —Not reported
- Tertomotide
- —Trial running · NCT05303701
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AAV-hTERT: no structured comparison results are available for Alzheimer's Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AAV-hTERT's landscape · Tertomotide's landscape